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Abstract
Telomerase reverse transcriptase (TERT) and telomerase RNA (TR) represent the enzymatically active components of
telomerase. In the complex, TR provides the template for the addition of telomeric repeats to telomeres, a protective
structure at the end of linear chromosomes. Human TR with a mutation in the template region has been previously shown
to inhibit proliferation of cancer cells in vitro. In this report, we examined the effects of a mutation in the template of a virus
encoded TR (vTR) on herpesvirus-induced tumorigenesis in vivo. For this purpose, we used the oncogenic avian herpesvirus
Marek’s disease virus (MDV) as a natural virus-host model for lymphomagenesis. We generated recombinant MDV in which
the vTR template sequence was mutated from AATCCCAATC to ATATATATAT (vAU5) by two-step Red-mediated
mutagenesis. Recombinant viruses harboring the template mutation replicated with kinetics comparable to parental and
revertant viruses in vitro. However, mutation of the vTR template sequence completely abrogated virus-induced tumor
formation in vivo, although the virus was able to undergo low-level lytic replication. To confirm that the absence of tumors
was dependent on the presence of mutant vTR in the telomerase complex, a second mutation was introduced in vAU5 that
targeted the P6.1 stem loop, a conserved region essential for vTR-TERT interaction. Absence of vTR-AU5 from the telomerase
complex restored virus-induced lymphoma formation. To test if the attenuated vAU5 could be used as an effective vaccine
against MDV, we performed vaccination-challenge studies and determined that vaccination with vAU5 completely
protected chickens from lethal challenge with highly virulent MDV. Taken together, our results demonstrate 1) that
mutation of the vTR template sequence can completely abrogate virus-induced tumorigenesis, likely by the inhibition of
cancer cell proliferation, and 2) that this strategy could be used to generate novel vaccine candidates against virus-induced
lymphoma.
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Introduction
Telomerase is a multi-component ribonucleoprotein complex
that governs the maintenance of telomeres, protein-associated
hexameric sequence repeats at the end of linear chromosomes,
and ensures chromosomal integrity and cellular survival [1,2]. The
telomerase complex consists of two core components, telomerase
reverse transcriptase (TERT) and telomerase RNA (TR). In the
complex, TR serves as the template for TERT, which catalyzes
the addition of telomeric repeats (TTAGGG)n at chromosome
ends [3]. Vertebrate TRs exhibit a universally conserved
secondary structure comprised of four structural domains (Fig.
1): the pseudoknot (core) domain containing the template sequence
in conserved region (CR) 1 (CR1), the CR4 and CR5 domains
with a highly conserved stem-loop structure (CR4-5), the H/ACA
box domain, and the CR7 domain [4]. CR1 encodes the template
sequence that is utilized for the extension of the telomeric repeats,
while the CR4-5 domain contributes to the processivity of
telomerase and is essential for stable assembly with TERT. The
H/ACA box and CR7 domains confer TR stability [4–6].
Telomerase activity is absent in most somatic cells, but
commonly up-regulated in rapidly dividing cells including
transformed cells [7]. Consistent with this observation, telomerase
activity is significantly elevated in over 85% of human cancers and
over 70% of immortalized human cell lines [8]. The absence of
telomerase activity often leads to progressive telomere shortening
resulting in cellular senescence and irreversible cell cycle arrest [9].
Several tumor-inducing viruses have evolved strategies to evade or
subvert mechanisms controlling cellular senescence, mainly via the
up-regulation of TERT, which is generally the limiting factor for
telomerase activity [10–13]. It has been suggested that up-
regulation of TERT expression and, consequently, increased
telomerase activity ensures the proliferative potential of persistent-
ly infected cells.
One of the most efficient viruses with respect to induction of
fatal tumors is Marek’s disease virus (MDV). MDV is a
PLoS Pathogens | www.plospathogens.org 1 October 2011 | Volume 7 | Issue 10 | e1002333lymphotropic herpesvirus that causes a well-described syndrome,
Marek’s disease (MD), in chickens. MD is characterized by
neurological disorders, immune suppression, and malignant T cell
lymphomas [14]. The rapid onset of lymphomas developing within
2 to 3 weeks post-infection (p.i.) and high tumor-induced
mortalities of 90–100% in susceptible chickens make MDV-
induced transformation an ideal model to study virus-induced
tumorigenesis in a natural virus-host setting [15]. A number of
MDV-encoded genes have been shown to be involved in MDV-
induced transformation. The major MDV oncogene, meq, encodes
a basic leucine zipper (bZIP) transcription factor similar to the
cellular homologues c-Jun, c-Fos, and c-Myc. Meq dimerizes with
other bZIP transcription factors and modulates expression of both
cellular and viral genes [16,17]. MDV also encodes other genes
products and sequence elements, which perform auxiliary
functions in transformation [18]. One such element is a TR
homologue termed viral TR (vTR) that shares 88% sequence
identity with chicken TR (chTR) [19]. The high sequence
homology suggests vTR was likely acquired from the chicken
genome during virus-host co-evolution. Compared to its cellular
counterpart, chTR, interaction of vTR with TERT results in
higher telomerase processivity [20,21]. It was shown that vTR
contributes to the rapid onset of lymphoma formation by serving
as a template for TERT, but it also has functions that are
independent of the telomerase complex. It is predominantly the
telomerase-independent functions of vTR that are responsible for
tumor progression and dissemination [21,22].
In vitro experiments demonstrated that mutations in the template
sequence within CR1 of human and mouse TR can result in
telomere instabilities, aberrant chromosome separation and
segregation, and ultimately apoptosis [23,24]. TRs with a mutated
template can induce unique checkpoint responses that are different
from DNA damage or loss-of-telomerase responses, even at low
mutant TR expression levels and in the presence of wild-type TR.
In addition, pro-apoptotic effects were also shown for TRs
harboring mutant template or oligonucleotides specifying mutant
template sequences and such molecules are discussed as anti-
tumor therapeutics in different types of cancers [23,25,26].
Here, we investigated the effect of a mutant vTR template
sequence (AU5) on the tumor-promoting capacity of a highly
oncogenic avian herpesvirus in its natural host. Mutation of the
template sequence of MDV-encoded vTR completely abrogated
virus-induced tumor formation in chickens. Introduction of a
second mutation in the stem loop (CR4-5) region that abolishes a
Figure 1. Schematic diagram of MDV vTR secondary structure,
location of the CR1 and CR4-5 domains, and incorporated
mutations. A) The pseudoknot (core), containing the template
sequence, and the CR4-CR5 domains containing the P6.1 stem loop,
are indicated with boxes. B) The pseudoknot domain including the
sequence of wild-type vTR template and AU5 template mutant (AU5).
Nucleotide changes in the template sequence are shown in red. C) The
CR4-CR5 domain showing detailed representations of the P6.1 stem-loop
and the structures of wild-type P6.1 (left) and mutant P6.1 stem-loop
(P6.1mut)(right) areshown.NucleotidechangesofthewtP6.1 stem-loop
(blue) are shown in red and have been previously published [22].
doi:10.1371/journal.ppat.1002333.g001
Author Summary
Telomerase facilitates telomere maintenance and consists
of two major components: the catalytic subunit telome-
rase reverse transcriptase (TERT) and telomerase RNA (TR)
that provides the template for the addition of telomeric
repeats to telomere ends. Expression of TRs with a
mutation in the template sequence can result in telomere
instability, cell cycle arrest and apoptosis in mammalian
cells. Here, we introduced a template mutation in a TR
encoded by the highly oncogenic avian herpesvirus
Marek’s disease virus (MDV) to evaluate this mechanism
in a natural virus-host model for virus-induced tumorigen-
esis. Expression of the mutant viral telomerase RNA (vTR)
by MDV allowed virus replication in telomerase-deficient
cells, but completely abrogated MDV-induced lymphoma-
genesis in vivo in a telomerase-dependent manner.
Infection with MDV harboring the template mutation in
vTR not only abrogated herpesvirus-induced tumorigene-
sis, but also protected chickens from lethal challenge with
a very virulent MDV strain. We provide the first in vivo
evidence that a TR with a template mutation expressed by
a herpesvirus can be used to prevent herpesvirus-induced
tumorigenesis, an approach that could be used for the
development of the next generation vaccines against MDV
and possibly also other lymphotropic herpesviruses.
Mutant vTR Abrogates Virus-Induced Lymphomagenesis
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genesis, confirming that the abrogation of tumorigenesis shown for
the mutant virus is dependent on telomerase activity through
interaction of mutant vTR and TERT. In vaccination-challenge
studies, the virus expressing mutant template protected chickens
from lethal challenge with a very virulent MDV strain.
Results
Expression of mutant template sequence vTR
significantly reduces proliferation of avian cancer cells in
vitro
TRs harboring mutations in the template sequence were
previously shown to result in telomere instabilities, aberrant
chromosome separation and segregation, and ultimately apoptosis
in mammalian cells in vitro [23]. Led by these previous
observations, we hypothesized that expression of vTR encoding
a mutated template sequence (AATCCCAATC to ATATATA-
TAT), termed AU5, could have an effect on avian cancer cells that
is similar to that described previously for mammalian cells [23,24].
In order to test our hypothesis, we first screened a number of avian
primary cells and permanent cancer cell lines to determine the
optimal system that would provide sufficient levels of telomerase
activity. We performed telomere repeat amplification protocol
(TRAP) assays to detect telomerase activity in primary chicken
embryo cell (CEC) cultures, the chicken fibroblast cell line DF-1
[27], and the quail cancer cell line QT35 [28]. CEC and DF-1
cells did not exhibit telomerase activity, while the QT35 cancer
cell had high telomerase activity as evidenced by the presence of
numerous TRAP products (Fig. 2A). A DF-1 cell line stably
expressing TERT showed some telomerase activity, suggesting
that TERT was the limiting factor for telomerase activity in this
cell line. Based on the results, we used a previously established
QT35 cancer cell line that allowed tetracycline-inducible expres-
sion [29] of vTR or vTR-AU5 (AU5). During the establishment of
cell lines we observed that even un-induced AU5 cell lines
replicated markedly slower. From many initial clones, only a single
monoclonal AU5 cell line could be established, suggesting a strong
selection against leaky AU5 expression. This effect has been
previously observed during the development of mammalian cell
lines expressing TR template mutants [23]. Therefore, polyclonal
vTR and AU5 cell lines were used to determine the effect of AU5
expression on cancer cell proliferation. RT-qPCR analysis of
polyclonal cells, confirmed leaky expression of the constructs and
that vTR and AU5 expression could be increased by more than
300-fold upon induction with doxycycline after 5 days of treatment
(Fig. 2B).
To determine if AU5 inhibits cancer cell proliferation, we
analyzed colony formation by measuring confluency over 31 days
in the presence or absence of doxycycline. Constitutive or induced
expression of wild-type vTR resulted in enhanced proliferation
when compared cells harboring the vector control as described
previously [21]. In contrast, cell lines harboring AU5 exhibited a
significant growth defect when compared to vTR and control cell
lines (Fig. 2C). Increased expression of AU5 following induction
resulted in only slightly reduced cell proliferation when compared
with non-induced cells, suggesting that expression of only low
levels of AU5 are sufficient to reduce growth of the QT35 cancer
cell line. We concluded that our results are consistent with those of
TR over-expression in human and murine cancer cells [23,24] and
show that expression of the MDV vTR can help stabilize and/or
promote growth, while mutation of the template sequence
significantly impairs proliferation of the avian QT35 cancer cell
line.
Mutation of the vTR template sequence abrogates MDV-
induced lymphomagenesis
Since mutation of the template sequence of vTR resulted in
decreased proliferation of QT35 cancer cells (Fig. 1C), we
hypothesized that the mutation in the context of virus infection
may have an effect on MDV replication and tumorigenesis in vivo.
Therefore, we mutated the template sequence of vTR (AU5) in
pRB-1B, an infectious bacterial artificial chromosome (BAC) clone
of the highly oncogenic RB-1B MDV strain using two-step Red-
mediated recombination [30,31]. Two rounds of mutagenesis
allowed the desired alteration of both copies of the diploid vTR
gene within the MDV genome, and transfection of the
recombinant BAC clone into CEC resulted in the reconstitution
of the vTR template mutant virus (vAU5). Furthermore, a
revertant clone (AU5rev) was generated in which the wild-type
template sequence was restored in the mutant vAU5. Following
virus reconstitution, we performed plaque size assays and multi-
step growth kinetics in CEC that revealed that the growth
properties of vAU5 were indistinguishable from those of parental
(vRB-1B) and revertant (vAU5rev) viruses (Fig. 3A–D).
Next, we determined if expression of AU5 had an effect on
MDV replication, disease, and tumor incidence in vivo. In two
independent experiments, we infected 1-day-old P2a chickens with
vRB-1B, vAU5, or vAU5rev and monitored virus levels in the
blood using qPCR assays until 28 days post infection (dpi). vAU5
replication was significantly impaired when compared to parental
and revertant viruses, indicating that the number of infected B and
T cells is reduced (Fig. 4B and D). Consistent with the reduction of
viremia, none of the chickens infected with vAU5 developed
tumors in two independent experiments (0/10; 0/18) over the
course of 13 weeks while parental (vRB-1B) or revertant (vAU5rev)
viruses induced lymphomas in 92–100% of infected animals
(Fig. 4A and C). We concluded from our data that expression of
vTR harboring the AU5 mutation by MDV can completely
abrogate virus-induced tumorigenesis in highly susceptible chick-
ens, most likely by the elimination of MDV-infected and/or
transformed cells by apoptosis.
Abrogation of MDV-induced lymphomagenesis caused
by expression of mutant vTR is dependent on its
interaction with TERT
We previously demonstrated that a mutation within the vTR
P6.1 stem-loop can prevent incorporation of vTR into the
telomerase complex and abolish enzymatic activity and telomere
elongation [22]. To confirm that the absence of lymphoma in
vAU5-infected animals was dependent on the presence of AU5 in
the telomerase complex, we constructed mutant viruses in which
the AU5 and P6.1 mutations were introduced into vTR either
individually or together. Revertant viruses of each mutation were
also generated. All constructed viruses replicated with kinetics
comparable to those of parental and revertant viruses in vitro
(Fig. 5). Upon infection of chickens with the recombinant viruses,
qPCR analysis revealed that insertion of the P6.1 mutation into
vAU5 (vAU5+P6.1mut) restored lytic virus replication to levels
comparable to those of parental vRB-1B, while mutant virus only
harboring the AU5 mutation (vAU5+P6.1rev) was significantly
impaired in replication (Fig. 6A).
Like vAU5, vAU5+P6.1rev did not induce tumors in any of the
infected chickens (0/19) (Fig. 6B). Two of the 19 chickens (11%)
died over the course of the 13 week experiment, which was likely
due to immunosuppression and generalized wasting, common
characteristics of MD and observed in earlier reports using viruses
that are unable to express vTR [21]. Viruses that contained the
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PLoS Pathogens | www.plospathogens.org 3 October 2011 | Volume 7 | Issue 10 | e1002333Figure 2. Expression of vTR harboring the mutant template (AU5) decreases cell proliferation of an avian cancer cell line. A) Analysis
of telomerase activity in primary CEC cultures, the chicken fibroblast cell line DF-1 with or without TERT expression, and the quail QT35 cancer cell line
using TRAP assays. TRAP products representing telomere elongation and internal control (IC) are indicated. B) RT-qPCR of vTR copies in polyclonal
empty vector, vTR or AU5 QT35 cell lines induced with 1 mg/ml doxycycline (Dox) for 3 and 5 d or left uninduced. Data is shown as relative
quantitation (RQ) of vTR copies relative to quail GAPDH RNA copies that served as an endogenous control. C) Percent (%) confluency of vector, vTR,
and AU5 cell lines over the course of 31 d. Results are shown as means and standard errors of three independent experiments. P values were
determined between each group using Student’s t tests.
doi:10.1371/journal.ppat.1002333.g002
Figure 3. MDV harboring a template mutant vTR replicate comparable to parental and revertant viruses in vitro. A–B) Plaque areas
were determined for 35 (A) or 100 (B) randomly selected plaques for indicated viruses. Results are shown as mean plaque areas in percent of the
parental vRB-1B with standard deviations (error bars). C–D) Multi-step growth kinetics of indicated viruses were performed in triplicates and are
shown as means with standard deviations (error bars).
doi:10.1371/journal.ppat.1002333.g003
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in 100% of infected animals. Furthermore, vP6.1, parental and
complete revertant viruses caused tumors in all animals infected
with the respective viruses. From the results we concluded that
abrogation of lymphoma formation after infection with an MDV
specifying the AU5 template mutation is indeed dependent on the
interaction of template mutant vTR with TERT and has no effect
if it is not incorporated into the telomerase complex.
Vaccination with vTR template mutant virus confers
protection against lethal MDV challenge
Since MDV harboring the template mutant vTR did not induce
tumors but still replicated in chickens, we addressed the question
whether vAU5 could induce a robust enough immune response to
serve as a vaccine. Groups of 1-day-old P2a (highly susceptible to
MD) and N2a (partially resistant to MD) chickens were inoculated
with diluent, vAU5, or the widely used, commercial vaccine strain
CVI988. Vaccinated chickens were challenged 10 days later with
the very virulent RB-1B MDV strain. Chickens receiving the
diluent developed tumors with expected frequencies of 100% in
the P2a chickens and 79% in the N2a chickens after 13 weeks
(Fig. 7A and B) [32]. vAU5 vaccinated N2a chickens were
completely protected from lethal challenge, while 7% of the
animals vaccinated with the commercial CVI988 vaccine strain
developed disease with a protective index of 91%. In P2a chickens
that are highly susceptible to MD, both vAU5 and CVI988
Figure 4. Tumor induction and in vivo replication of MDV
harboring mutant template sequence (AU5) vTR. MD-susceptible
chickens were inoculated with 1,000 PFU of either vRB-1B (n=12) or
vAU5 (n=11) in experiment 1 (A and B) and 2,000 PFU of vRB-1B
(n=17), vAU5 (n=19), or vAU5rev (n=17) in experiment 2 (C and D). A
and C) Necropsies were performed on chickens following onset of
clinical signs of MD during both experiments and the percent of
infected chickens developing tumors over 13 wk was determined. B and
D) DNA was obtained from peripheral blood of chickens infected with
each respective virus and viral genome copies were determined using
qPCR assays. MDV ICP4 copies were normalized to the chicken iNOS
gene and are shown as MDV genome copies per 1610
6 cells with
standard error of mean bars. Viremia induced by vAU5 was significantly
reduced when compared to vRB-1B (in experiment B) 14dpi, p=0.007;
21dpi, p= 0.003; 28dpi, p=0.014; in experiment D) 14dpi, p=0.013;
21dpi, p=0.004; 28dpi, p=0.049) and vAU5rev (in experiment D) 10dpi,
p=0.022; 14dpi, p=0,003) at the time points indicated by asterisks (*)
using Student’s t tests.
doi:10.1371/journal.ppat.1002333.g004
Figure 5. In vitro replication of parental, mutant, and revertant
viruses. Plaque areas were determined for 100 randomly selected
plaques for the indicated viruses. Results are shown as mean plaque
areas in percent of the parental vRB-1B with standard deviations (error
bars).
doi:10.1371/journal.ppat.1002333.g005
Figure 6. Secondary mutation of the vTR-TERT interaction
domain, P6.1, rescues MDV replication and lymphomagenesis.
MD-susceptible chickens were infected with vRB-1B (n=17), vP6.1mut
(n=16), vAU5 + P6.1mut (n=18), vAU5 + P6.1rev (n=19), or vAU5rev +
P6.1rev (n=18). A) DNA was obtained from blood of infected chickens
and MDV genome copies are shown per 1610
6 cells as in Fig. 3.
Significant differences in genome copies between vAU5 + P6.1rev and
vRB-1B (14dpi, p=0.013; 21dpi, p=0.004; 28dpi, p=0.049) and vAU5rev
+ P6.1rev (14dpi, p=0.002) are indicated with an asterisk (*) using
Student’s t test. B) Tumor incidences for each group infected with
viruses contained only the AU5 mutation (empty boxes), additional/
exclusively the P6.1 mutation (grey symbols) or parental and complete
revertants (black symbols) were measured for 13 weeks.
doi:10.1371/journal.ppat.1002333.g006
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animal in each group developed disease. The protective index of
vAU5 and CVI988 in P2a animals was 93% and 92%,
respectively. These results suggest that mutation of the template
region of vTR in a virulent MDV can serve as a strategy to induce
protection against virus-induced lymphomas.
Discussion
We here report on effects of a mutation in the template
sequence (CR1) of vTR encoded by MDV on virus replication and
tumorigenesis in a natural virus-host model. Mutation of the vTR
template sequence from AATCCCAATC to ATATATATAT
(AU5) resulted in decreased proliferation of the QT35 avian
cancer cell line (Fig. 2), as had been described for TR in
mammalian cells [23,24]. Introduction of the template sequence
mutation in vTR in the context of the viral genome and infection
of MD-susceptible chickens with mutant virus (vAU5) resulted in
complete absence of tumors and low-level viral replication in vivo
(Fig. 4). Secondary mutation of the vTR stem-loop sequence
(P6.1), abolishing the interaction of mutant vTR with TERT,
restored virus-induced tumorigenesis (Fig. 6), thus showing that
vTR-TERT interaction and functional telomerase activity is
required for the anti-tumorigenic effects of the mutant template
sequence in a viral background. Vaccination with MDV harboring
the vTR template mutation not only abrogated herpesvirus-
induced tumorigenesis, but also protected chickens from a lethal
challenge with a very virulent MDV strain.
We surmise that the reduced proliferation of QT35 expressing
vTR with a template sequence mutation, as well as the absence of
tumors and greatly reduced lytic replication in chickens are both
caused by the incorporation of mutant telomeric repeat sequences
into host telomeres of infected cells, which eventually leads to
telomere crisis and apoptosis (Fig. 8). This sequence of events has
been shown previously in other mammalian systems in vitro, where
even low levels of mutant TR induced a unique checkpoint
response resulting in telomere instabilities, aberrant chromosome
separation and segregation, and apoptosis [23,24]. In addition, the
pro-apoptotic effect of TRs harboring mutant templates or
oligonucleotides specifying mutant template sequences has also
been shown [23,25,26].
It is interesting to note that the QT35 cancer cell line was
previously shown to maintain MDV in a latent state [33] and that
the cells express MDV vTR at very low levels (Fig. 2B). Despite the
expression of endogenous quail TR and MDV vTR, AU5
expression had a negative effect on the replication of QT35
cancer cells. Consequently, induced over-expression of wild-type
vTR led to increased proliferation of QT35 cancer cells, further
lending support to the interpretation that vTR performs an
important function in the early maintenance of transformed cells
[21]. Induced expression of the AU5 sequence leading to
incorporation of mutant template sequences significantly reduced
proliferation presumably by inducing apoptosis, again consistent
with previous studies on mammalian TRs [23].
vTR was previously shown to contribute to MDV-induced
lymphomagenesis. Deletion of vTR in the MDV genome resulted
in significantly reduced tumor incidences but the mutation did not
affect virus replication in vivo [21]. Mutation of the vTR template
region (AU5) in MDV, however, completely abrogated tumori-
genesis and reduced viral loads in infected animals, likely via
inhibition of cancer cell replication through induction of apoptosis.
vTR has at least two functions during lymphomagenesis, one that
is dependent and one that is independent of telomerase activity.
The telomerase-dependent function plays an important role in the
early onset of disease but is dispensable for tumorigenesis. This
conclusion is supported by studies showing that MDV harboring a
mutated vTR incapable of interaction with TERT (P6.1mut) can
still induce tumors in chickens, albeit resulting in a delayed onset
of tumor formation [22]. vTR functions that are independent of its
presence in the telomerase complex seem to be important for
lymphomagenesis but are poorly understood. We utilized this
previously published mutation to determine if the induction of
apoptosis and abrogation of tumorigenesis is dependent on the
incorporation of AU5 into the telomerase complex. While MDV
harboring AU5 vTR are incapable of inducing tumors, mutation
in the vTR-TERT interaction domain (vAU5+P6.1mut) in vAU5
completely restored tumorigenesis.
We therefore concluded that restored ability of vAU5+P6.1mut
to induce tumors is presumably caused by the inability of the
telomerase to incorporate mutant telomeric repeats at the ends of
host chromosomes and cause telomere crisis and apoptosis; hence
the pro-oncogenic functions of vTR that are independent of the
telomerase complex prevail. Our results demonstrate that
vAU5+P6.1mut can efficiently cause lymphoma, which confirms
that vTR has tumor-promoting functions independent of the
telomerase complex and that they are mediated by a vTR domain
outside of the template region.
The fact that vAU5 was unable to induce tumors in highly
susceptible P2a chickens suggested that it could serve as a potential
vaccine against MD. Vaccination with vAU5 protected chickens
from lethal challenge infection with the very virulent MDV strain
RB-1B at least as efficiently as the commercial vaccine strain
Figure 7. Immunization with the vAU5 mutant viruses protects
chickens from lethal MDV infection. A) MD-incidence in N2a (A;
n=14) and B) P2a (B; n=14) chickens vaccinated with either vAU5,
CVI988 or media alone (Mock) before challenge-infection with RB-1B.
Precent protection from the onset of disease or being tumor-positive at
termination of the experiment is shown in % of the animals.
doi:10.1371/journal.ppat.1002333.g007
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However, the residual mortality observed in some chickens has
to be clarified to ensure the safety of the vaccine candidate. A
similar phenomenon of low levels of mortality in highly susceptible
birds, similar to the one observed here, was also observed with
MDV mutants in which the major oncoprotein of MDV, Meq,
was absent. Infection with meq deletion viruses did not cause
tumors [35], but severe lymphoid atrophy and immunosuppres-
sion was evident [36]. Likely, a combination of vTR template
mutation with other modifications in the MDV genome targeting
genes important for replication could therefore increase the safety
of the vaccine and prevent lymphoid atrophy. Here, we suggest a
new strategy that could be applied to the next generation of MD
vaccines, which will certainly be needed because recently isolated
MDV strains are capable of evading immune protection provided
by current vaccines [15,37,38].
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Committee on the Ethics of Animal
Experiments of Cornell University (permit number 2002-0085 and
2008-0018). The animal care facilities and programs of Cornell
University meet the requirements of the law (89–544, 91–579, 94–
276) and NIH regulations on laboratory animals, and are in
compliance with the Animal Welfare Act, PL 279. All experi-
mental procedures were in compliance with approval of Cornell
University’s Institutional Animal Care and Use Committee
(IACUC) and all efforts were made to minimize suffering.
Generation of mutant MDV
Recombinant viruses were generated by two-step Red-mediated
recombination as previously described [30,31]. Primers used for
construction of template sequence (CR1) AU5 mutants (vAU5)
and revertants (vAU5rev) are shown in Table 1. Primers used for
construction of the P6.1 vTR-TERT interaction domain mutants
and revertants have previously been published [22].
Propagation of MDV
CEC cultures were prepared from 10-day-old specific-patho-
gen-free (SPF) embryos using standard methods [39]. Recombi-
nant viruses were reconstituted from purified BAC DNA in CEC
cultures using CaPO4 transfection [40]. The loxP flanked mini-F
Figure 8. Proposed model for abrogation of tumor induction by mutant template sequence vTR through incorporation of mutant
telomere sequences in transformed T cells. Expression of vTR AU5 leads to telomere instabilities, aberrant chromosome separation and
segregation, and finally apoptosis induction in the presence of TERT (upper panel). Without vTR interaction with TERT by mutation of the P6.1 stem
loop, mutant template sequences (AU5) are not incorporated in the telomeres of transformed cells and thus proliferation of transformed cells
continues, leading to lymphomas.
doi:10.1371/journal.ppat.1002333.g008
Mutant vTR Abrogates Virus-Induced Lymphomagenesis
PLoS Pathogens | www.plospathogens.org 7 October 2011 | Volume 7 | Issue 10 | e1002333sequences within the infectious clones were removed by co-
transfection with a Cre recombinase expression vector (pCAGGS-
NLS/Cre) as previously described and screened via analytical
PCR [30]. Virus propagation, plaque area measurements and
multi-step growth kinetics were also performed as described
previously [41].
Animal studies
SPF P2a (MHC haplotype B
19B
19) or N2a (MHC haplotype
B
21B
21) chickens were obtained from departmental flocks and
housed in poultry isolation units. Chickens were inoculated with
1,000 or 2,000 plaque forming units (PFU) of virus by intra-
abdominal injection and evaluated for symptoms of MD on a daily
basis. Necropsies were performed on chickens showing clinical
signs of MD, as well as all remaining chickens at the termination of
the experiment.
Chicken blood DNA extraction and qPCR assays
DNA was extracted from whole blood of eight chickens for each
group randomly selected prior to the experiment and MDV
genomic copies were determined by qPCR assays [41]. Briefly,
MDV DNA copy numbers were detected using primers and probe
specific for the MDV infected cell protein 4 (ICP4) locus that were
normalized to cellular genome copies of chicken inducible nitric
oxide synthase (iNOS).
Cloning of vTR and AU5 Tet-on expression constructs
and generation of stable cell lines
Tet-on constructs were generated by digestion of the pCMS-
vTR and pCMS-vTR-AU5 constructs previously described [22]
with EcoRI and XbaI. Resulting vTR or AU5 fragments were
then cloned into the pcDNA4/TO/myc-his vector (Invitrogen,
Carlsbad, CA) to generate pcDNA4/TO-vTR and pcDNA4/TO-
AU5, respectively.
Inducible cell lines were generated based on QT35TR19, a
previously described Tet-inducible QT35 cancer cell line (kindly
provided by Karel A. Schat, Cornell University) and maintained
as described previously [29]. To generate control, vTR, and AU5
expressing cell lines, QT35TR19 cells were transfected with
pcDNA4/TO (empty vector), pcDNA4/TO-vTR, or pcDNA4/
TO-AU5 using Lipofectamine2000 (Invitrogen, Carlsbad, CA)
following the manufacturer’s instructions. Monoclonal and
polyclonal cell lines were selected with 5 mg/ml blasticidin and
500 mg/ml zeocin (Invitrogen). All cell lines were used between
passage 5 and 10 in cell proliferation and RT-qPCR assays.
Cell proliferation assays
Proliferation of Tet-inducible cell lines was evaluated as
previously described [23]. Briefly, 2610
3 cells of each cell line
were seeded into 35 mm dishes in triplicate and maintained in
media with or without 1 mg/ml doxycycline with 2/3 media
changed every 4–5 days. After 31 days, cells were fixed with 90%
ice-cold acetone and stained with 1% crystal violet in 50%
methanol. Percent confluency was determined using NIH ImageJ
software by calculating the total area on the plates covered by cell
colonies over the total area of the plate. The average % confluency
was determined from three independent experiments.
RT-qPCR assays for analysis of Tet-inducible vTR
expression
One-thousand vTR, AU5, or empty vector Tet-inducible cells
were treated with or without 1 mg/ml doxycycline in triplicate.
After 3 and 5 days, total RNA was prepared using RNA STAT 60
as described previously [42]. Reverse transcription was performed
using the ThermoScriptTM RT-PCR system (Invitrogen, Carls-
bad, CA) with random hexamer oligonucleotides according to
manufacturer’s instructions.
Copies of vTR cDNA were determined by qPCR assays using
the TaqMan Fast Universal Master Mix system (Applied
Biosystems, Inc.) according to manufacturer’s instructions and
performed in an ABI Prism 7500 Fast Real-Time PCR System
(Applied Biosystems, Inc.). Results were analyzed with the
Sequence Detection Systems version V2.0.3 software using the
comparative Ct method (2
2DDCt) of relative quantification.
Primers and probe for the detection of MDV vTR and quail
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that served
as an endogenous control have been described previously [43,44].
Statistical analysis
Significant differences in % confluency assays and MDV
replication using qPCR assays were determined using Student’s t
test or Tukey-Kramer comparison of means.
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